原发肿瘤切除的IV期结直肠癌患者长期生存的预测因素:一项多中心回顾性分析

IF 2.8 3区 医学 Q3 ONCOLOGY
Kiyoaki Sugiura, Tatsuki Kato, Junya Aoyama, Go Oshima, Hiroto Kikuchi, Koji Okabayashi, Satoshi Aiko, Yuko Kitagawa
{"title":"原发肿瘤切除的IV期结直肠癌患者长期生存的预测因素:一项多中心回顾性分析","authors":"Kiyoaki Sugiura, Tatsuki Kato, Junya Aoyama, Go Oshima, Hiroto Kikuchi, Koji Okabayashi, Satoshi Aiko, Yuko Kitagawa","doi":"10.1007/s10147-025-02845-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Primary tumor resection is an option for patients with stage IV colorectal cancer (CRC). However, there is still no reliable strategy for predicting the survival of individual patients undergoing primary tumor resection (PTR). The aim of this study was to identify predictors of good prognosis in patients with stage IV CRC with PTR.</p><p><strong>Methods: </strong>This is a retrospective analysis of patients with stage IV CRC who had undergone PTR in the Keio Surveillance Epidemiology and End Results (K-SEER) database. Clinical data and short- and long-term outcomes were analyzed. Univariate and multivariate analyses were performed using Cox proportional hazards model including all survival-related variables.</p><p><strong>Results: </strong>Among 252 patients enrolled in this study, 176 had single-organ and 76 had multi-organ metastases. Seventy-seven patients did not receive chemotherapy after primary tumor resection. Three patients consequently underwent curative metastasectomy after PTR. Multivariate Cox analysis revealed age, number of organs with metastasis, and chemotherapy after PTR were independently associated with both Overall Survival (OS) and Cancer-Specific Survival (CSS). In the subgroup analysis, the survival rate was significantly lower in patients with multi-organ metastases than in those with single-organ metastases, both in 3-year OS (47.69% vs 23.20%; log-rank P < 0.001) and 3-year CSS (54.45% vs 30.48%; log-rank P < 0.001).</p><p><strong>Conclusions: </strong>This study demonstrated that multi-organ metastasis was a prognostic factor for poor prognosis in patients with stage IV CRC patients who underwent PTR. These findings could support surgeons to make better clinical decisions for patients with stage IV CRC.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2032-2042"},"PeriodicalIF":2.8000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Predictors of long‑term survival in patients with stage IV colorectal cancer with primary tumor resection: a multi-center retrospective analysis.\",\"authors\":\"Kiyoaki Sugiura, Tatsuki Kato, Junya Aoyama, Go Oshima, Hiroto Kikuchi, Koji Okabayashi, Satoshi Aiko, Yuko Kitagawa\",\"doi\":\"10.1007/s10147-025-02845-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Primary tumor resection is an option for patients with stage IV colorectal cancer (CRC). However, there is still no reliable strategy for predicting the survival of individual patients undergoing primary tumor resection (PTR). The aim of this study was to identify predictors of good prognosis in patients with stage IV CRC with PTR.</p><p><strong>Methods: </strong>This is a retrospective analysis of patients with stage IV CRC who had undergone PTR in the Keio Surveillance Epidemiology and End Results (K-SEER) database. Clinical data and short- and long-term outcomes were analyzed. Univariate and multivariate analyses were performed using Cox proportional hazards model including all survival-related variables.</p><p><strong>Results: </strong>Among 252 patients enrolled in this study, 176 had single-organ and 76 had multi-organ metastases. Seventy-seven patients did not receive chemotherapy after primary tumor resection. Three patients consequently underwent curative metastasectomy after PTR. Multivariate Cox analysis revealed age, number of organs with metastasis, and chemotherapy after PTR were independently associated with both Overall Survival (OS) and Cancer-Specific Survival (CSS). In the subgroup analysis, the survival rate was significantly lower in patients with multi-organ metastases than in those with single-organ metastases, both in 3-year OS (47.69% vs 23.20%; log-rank P < 0.001) and 3-year CSS (54.45% vs 30.48%; log-rank P < 0.001).</p><p><strong>Conclusions: </strong>This study demonstrated that multi-organ metastasis was a prognostic factor for poor prognosis in patients with stage IV CRC patients who underwent PTR. These findings could support surgeons to make better clinical decisions for patients with stage IV CRC.</p>\",\"PeriodicalId\":13869,\"journal\":{\"name\":\"International Journal of Clinical Oncology\",\"volume\":\" \",\"pages\":\"2032-2042\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10147-025-02845-8\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/29 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10147-025-02845-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/29 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:原发性肿瘤切除术是IV期结直肠癌(CRC)患者的一种选择。然而,目前仍没有可靠的策略来预测接受原发性肿瘤切除术(PTR)的个体患者的生存。本研究的目的是确定IV期结直肠癌伴PTR患者预后良好的预测因素。方法:回顾性分析庆应义塾监测流行病学和最终结果(K-SEER)数据库中接受PTR治疗的IV期结直肠癌患者。分析临床资料及短期和长期结果。采用包含所有生存相关变量的Cox比例风险模型进行单因素和多因素分析。结果:本研究纳入的252例患者中,176例为单器官转移,76例为多器官转移。77例患者原发肿瘤切除后未接受化疗。3例患者在PTR后接受了根治性转移切除术。多因素Cox分析显示,年龄、转移器官数量和PTR后化疗与总生存期(OS)和肿瘤特异性生存期(CSS)独立相关。在亚组分析中,多器官转移患者的3年生存率明显低于单器官转移患者(47.69% vs 23.20%;结论:本研究表明,多器官转移是IV期结直肠癌患者行PTR后预后不良的一个预后因素。这些发现可以支持外科医生对IV期CRC患者做出更好的临床决策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Predictors of long‑term survival in patients with stage IV colorectal cancer with primary tumor resection: a multi-center retrospective analysis.

Background: Primary tumor resection is an option for patients with stage IV colorectal cancer (CRC). However, there is still no reliable strategy for predicting the survival of individual patients undergoing primary tumor resection (PTR). The aim of this study was to identify predictors of good prognosis in patients with stage IV CRC with PTR.

Methods: This is a retrospective analysis of patients with stage IV CRC who had undergone PTR in the Keio Surveillance Epidemiology and End Results (K-SEER) database. Clinical data and short- and long-term outcomes were analyzed. Univariate and multivariate analyses were performed using Cox proportional hazards model including all survival-related variables.

Results: Among 252 patients enrolled in this study, 176 had single-organ and 76 had multi-organ metastases. Seventy-seven patients did not receive chemotherapy after primary tumor resection. Three patients consequently underwent curative metastasectomy after PTR. Multivariate Cox analysis revealed age, number of organs with metastasis, and chemotherapy after PTR were independently associated with both Overall Survival (OS) and Cancer-Specific Survival (CSS). In the subgroup analysis, the survival rate was significantly lower in patients with multi-organ metastases than in those with single-organ metastases, both in 3-year OS (47.69% vs 23.20%; log-rank P < 0.001) and 3-year CSS (54.45% vs 30.48%; log-rank P < 0.001).

Conclusions: This study demonstrated that multi-organ metastasis was a prognostic factor for poor prognosis in patients with stage IV CRC patients who underwent PTR. These findings could support surgeons to make better clinical decisions for patients with stage IV CRC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.80
自引率
3.00%
发文量
175
审稿时长
2 months
期刊介绍: The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信